CIPLA LTD.
DATE: 27/07/2025
SECTOR: PHARMACEUTICALS
INDUSTRY: PHARMA, GENERICS, API MANUFACTURING
|
CMP |
MARKET CAP |
52 WEEKs HIGH |
52 WEEKs LOW |
|
1532 |
123788 CR |
1702 |
1335 |
COMPANY OVERVIEW:
Cipla Ltd., a pioneer in India’s pharmaceutical space, is engaged
in the development, manufacturing, and marketing of branded and generic
formulations and Active Pharmaceutical Ingredients (APIs). With a history
spanning over 85 years, Cipla serves over 80 countries with 1,500+ products
across 65 therapeutic categories. Cipla is one of India’s oldest and most
reputed pharmaceutical companies, engaged in the development, manufacturing,
and global marketing of branded and generic formulations, APIs, and consumer
healthcare products. The company has a presence in over 80 countries, offering
1,500+ products across 65 therapeutic categories. Cipla is a market leader in
respiratory therapy and holds dominant positions in urology and
anti-infectives. Cipla operates 47 manufacturing sites across six countries and
has over 7,500 field staff promoting its portfolio. The company’s
customer-facing brands like Nicotex, Cofsils, and Omnigel have strong retail
penetration.
BUSINESS
SEGMENTS:
KEY POINTS:
Revenue:
Net Profit (Profit for the period attributable to shareholders):
Quarterly Operating Profit Margin (OPM - EBITDA %):
EPS
·
16.1 VS 11.6 YOY
KEY RATIOS:
|
PE |
PBV |
ROCE |
DEBT to EQUITY |
|
23 |
3.97 |
22.7% |
0.01% |
STRENGTHS:
WEAKNESSES:
OPPORTUNITIES:
THREATS:
KEY SHAREHOLDING
(JUN 2025):
TECHNICAL ANALYSIS (DAILY TIMEFRAME):
OVERALL
ASSESSMENT:
Cipla Ltd. presents a fundamentally strong, diversified and
well-positioned player in both domestic and global pharmaceutical space. It
leads in key therapy areas like Respiratory and Urology while maintaining a
strong foothold in generics and APIs across the globe. Its forward-looking
strategy, including green energy, biologics, and genomics, sets a strong
foundation for long-term sustainable growth. Despite modest topline growth,
Cipla’s strong ROE, healthy balance sheet, expanding consumer health division,
and digital transformation position it as a solid long-term investment in the
healthcare sector.
CONCLUSION:
Cipla Ltd. presents a fundamentally strong, diversified and
well-positioned player in both domestic and global pharmaceutical space. Its
clean balance sheet, market dominance in key therapies, and push into
future-focused areas like diagnostics and biologics add long-term value.
DISCLAIMER
Stock market investment/trading is subject to market risk. This
report has been prepared by THE MONEY MINT the marketing name of the RITU
CHAUHAN SEBI (Research Analyst) (Registration No. INH000014456) and is solely
for information of the recipient only. The report must not be used as a
singular basis for any investment decision. The views herein are general and do
not consider the risk appetite or the particular circumstances of an individual
investor; readers are requested to take professional advice before investing.
Nothing in this document should be construed as investment advice. Each
recipient of this document should make such investigations as they deem
necessary to arrive at an independent evaluation of an investment in securities
of the companies referred to in this document and should consult their advisors
to determine the merits and risks of such investment. The information and
opinions contained herein have been compiled or arrived at, based upon
information obtained in good faith from publicly available sources. Such
information has not been independently verified and no guarantee,
representation of warranty, express or implied, is made as to its accuracy,
completeness or correctness. All such information and opinions are subject to
change according to market scenarios. Descriptions of any company or companies
or their securities mentioned herein are not intended to be complete. THE MONEY
MINT or RITU CHAUHAN or associates are not obliged to update this report for
such changes. THE MONEY MINT or RITU CHAUHAN or the associates are not
responsible for profit or loss.
CONTACT: themudrakaars001@gmail.com
2025 Mudrakaar - All Rights Reserved.